STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAMSW
  4. [Form 4] NewAmsterdam Pharma Co N.V. Insider Trading Activity

NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported a combination of option exercises and share sales involving the company’s ordinary shares. On June 22, 2026, she exercised options to acquire a total of 40,000 ordinary shares through two transactions of 15,000 and 25,000 shares at exercise prices of $11.90 and $10.90 per share, respectively.

On the same date, she executed open-market sales totaling 40,000 ordinary shares in two transactions: 39,700 shares at $30.20 per share and 300 shares at a weighted average price of $30.73, with individual trade prices ranging from $29.73 to $30.72 per share. Following these transactions, her direct holdings continue to include 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

Positive

  • None.

Negative

  • None.
Insider Kooij Louise Frederika
Role Chief Accounting Officer
Sold 40,000 shs ($1.21M)
Type Security Shares Price Value
Exercise Option (right to buy) 25,000 $0.00 --
Exercise Option (right to buy) 15,000 $0.00 --
Exercise Ordinary Shares 25,000 $10.90 $273K
Exercise Ordinary Shares 15,000 $11.90 $179K
Sale Ordinary Shares 39,700 $30.20 $1.20M
Sale Ordinary Shares 300 $30.73 $9K
Holdings After Transaction: Option (right to buy) — 43,134 shares (Direct, null); Ordinary Shares — 49,353 shares (Direct, null)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Shares sold 40,000 shares Ordinary shares sold in open-market transactions on June 22, 2026
Sale price (large block) $30.20 per share Price for 39,700 ordinary shares sold
Weighted average sale price $30.73 per share 300-share sale; trades ranged from $29.73 to $30.72
Options exercised 40,000 shares 15,000 and 25,000 options exercised into ordinary shares
Option exercise price 1 $11.90 per share Exercise price for 15,000 options on ordinary shares
Option exercise price 2 $10.90 per share Exercise price for 25,000 options on ordinary shares
Unvested RSUs 22,000 ordinary shares Subject to restricted stock unit awards and vesting conditions
Option expiration dates 2033-01-01 and 2033-05-18 Expiration dates for the exercised option grants
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock unit financial
"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
option (right to buy) financial
"security_title: Option (right to buy)"
vesting financial
"shares underlying the option vest on the one-year anniversary of vesting start date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kooij Louise Frederika
(Last)(First)(Middle)
C/O NEWAMSTERDAM PHARMA COMPANY N.V.
GOOIMEER 2-35
(Street)
NAARDENNETHERLANDS1411 DC
(City)(State)(Zip)
NETHERLANDS
(Country)		2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/22/2026M25,000A$10.949,353D
Ordinary Shares06/22/2026M15,000A$11.964,353D
Ordinary Shares06/22/2026S39,700D$30.2(1)24,653(2)D
Ordinary Shares06/22/2026S300D$30.7324,353(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to buy)$10.906/22/2026M25,000 (3)01/01/2033Ordinary Shares25,000$0.0043,134D
Option (right to buy)$11.906/22/2026M15,000 (4)05/18/2033Ordinary Shares15,000$0.0035,000D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
2. Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
3. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
4. The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Remarks:
Reported transactions executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026.
/s/ Louise Kooij06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did NewAmsterdam Pharma (NAMS) report for Louise Frederika Kooij?

Louise Frederika Kooij reported exercising options for 40,000 ordinary shares and selling 40,000 ordinary shares on June 22, 2026. The activity combined option exercises at lower strike prices with open-market sales at around $30 per share.

How many NewAmsterdam Pharma (NAMS) shares did the Chief Accounting Officer sell?

The Chief Accounting Officer sold 40,000 ordinary shares in total. This included 39,700 shares at $30.20 per share and 300 shares at a weighted average price of $30.73, with trade prices ranging from $29.73 to $30.72 per share.

What option exercises did the NewAmsterdam Pharma (NAMS) Form 4 disclose?

The filing shows two option exercises converting 40,000 options into ordinary shares. Kooij exercised 15,000 options at $11.90 per share and 25,000 options at $10.90 per share, turning previously granted derivative awards into directly held ordinary shares.

Does Louise Frederika Kooij still hold NewAmsterdam Pharma (NAMS) equity after these transactions?

Yes. Her direct holdings continue to include 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. These RSUs represent ongoing equity exposure tied to future service and vesting conditions rather than immediate, freely tradable shares.

How were the NewAmsterdam Pharma (NAMS) share sales priced in the reported transactions?

The larger sale of 39,700 ordinary shares was priced at $30.20 per share. A separate 300-share sale used a weighted average price of $30.73 per share, with individual trades occurring between $29.73 and $30.72 per share across multiple executions.

What does the weighted average price disclosure mean in the NewAmsterdam Pharma (NAMS) Form 4?

The weighted average price of $30.73 reflects many small trades between $29.73 and $30.72. The insider notes a willingness to provide full detail on each individual trade to the issuer, its security holders, or SEC staff upon request, as is common in such disclosures.